Publication of Definitive Interim Result for Vifor Pharma Tender Offer: CSL Behring AG Declares Offer Successful

CSL Behring AG, a wholly-owned subsidiary of global biotechnology leader CSL Limited has announced the definitive notice of the Interim Result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022.

Taking into account the Vifor Pharma shares held by the offeror and the persons acting in concert with the offeror at the end of the main offer period and the Vifor Pharma shares tendered during the main offer period, CSL’s participation at the end of the main offer period on 2 March 2022 amounts to a total of 74 percent of all listed Vifor Pharma shares as of 2 March 2022, subject to the completion of the offer, the company said.

CSL highly appreciates this strong support of the combination with CSL by the Vifor Pharma shareholders and has waived the 80% acceptance rate condition set forth in the offer prospectus and declared the tender offer successful. The definitive notice of the Interim Result is available at www.csltransaction.com.

The additional acceptance period of 10 trading days for the subsequent acceptance of the tender offer will commence on 9 March 2022 and is expected to expire on 22 March 2022, 4 p.m. Swiss time, the company noted.